NYSE:ANRO Alto Neuroscience Q3 2026 Earnings Results & Report $28.75 +0.95 (+3.42%) Closing price 03:59 PM EasternExtended Trading$28.63 -0.12 (-0.42%) As of 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Alto Neuroscience beat analyst earnings expectations in its Q3 2026 results, released November 10, 2026. The company reported EPS of -$0.54 versus the -$0.6735 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 10, 2026TimeAfter Market ClosesConference Call4:00 PM ET Alto Neuroscience EPS ResultsActual EPS-$0.54Consensus EPS -$0.6735Beat/MissBeat by +$0.1335One Year Ago EPSN/AEPS Beat Rate6 of last 8 quartersAlto Neuroscience Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Alto Neuroscience Q3 2026 Earnings FAQ Did Alto Neuroscience beat earnings estimates for Q3 2026? Alto Neuroscience (NYSE:ANRO) reported earnings of -$0.54 per share for Q3 2026, beating the consensus estimate of -$0.6735. The report was announced on Tuesday, November 10, 2026. Alto Neuroscience Earnings HeadlinesAlto Neuroscience (ANRO) Stock Looks Fully Priced On Book ValueNovember 10 at 9:44 AM | finance.yahoo.comAlto Neuroscience (ANRO) Projected to Announce Quarterly Earnings on WednesdayNovember 10 at 2:57 AM | americanbankingnews.comTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Trading's Thomas Wood calls it one of the firm's most powerful proprietary trading indicators, and says the company has never run a deal like this before. There are no strings attached, just a steep Black Friday discount on a tool built for traders.November 10 at 1:00 AM | Base Camp Trading (Ad)Alto Neuroscience (NYSE:ANRO) Stock Price Breaks Above Two Hundred Day Moving Average - Should You Sell?November 7 at 4:35 AM | americanbankingnews.comHC Wainwright Adjusts Alto Neuroscience Price Target to $60 From $55, Maintains Buy RatingOctober 19, 2026 | marketscreener.comMAlto Neuroscience: Doubts Around Depression Candidate Merit Downgrade To HoldOctober 15, 2026 | seekingalpha.comSee More Alto Neuroscience Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Alto Neuroscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alto Neuroscience and other key companies, straight to your email. Email Address About Alto NeuroscienceAlto Neuroscience (NYSE:ANRO) is a clinical-stage biopharmaceutical company developing treatments for psychiatric and neurological conditions. The company uses neuroscience-based assessments, including brain activity and cognitive measures, to identify patient characteristics that may help guide treatment development and selection. Its investigational programs target conditions such as depression and other serious mental health disorders. Alto’s approach is intended to match treatments to biological or behavioral profiles rather than relying solely on diagnosis, with the goal of improving the development and use of therapies. Its drug candidates remain under clinical investigation and are not approved treatments. Founded in 2019 by neuroscientist Amit Etkin, Alto Neuroscience is based in the United States. Etkin has served as the company’s chief executive officer. The company’s research and clinical development focus is on advancing its precision-medicine approach in psychiatry.View Alto Neuroscience ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Why Kinder Morgan's Chairman Just Bought $15 Million in StockA $4 Billion Jolt: NRG Energy Powers Data Center AmbitionsD-Wave Quantum Has Long-Term Potential, But Is Now the Time to Buy?Archer Aviation's FAA Certificate Is a Milestone, But It Isn't the Final OneRocket Lab's Record Backlog Could Fuel a Rebound, But Neutron Raises the StakesDraftKings Just Lost 20%—And Its Biggest Gamble Is Still AheadBarrick's Earnings Beat Could Be Overshadowed by an Even Bigger Opportunity Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
